Skip to main content
Northwestern University Feinberg School of Medicine
Coronavirus/COVID-19 Updates
Skip to main content

COVID-19 Clinical Trials

Trials
Positive Affect Regulation sKills (PARK)

The Positive Affect Regulation sKills (PARK) Course is an online program that teaches positive emotion skills for individuals experiencing stress as a result of the COVID-19 outbreak, recommended/mandatory social distancing, and other related stressors (e.g…

The Positive Affect Regulation sKills (PARK) Course is an online program that teaches positive emotion skills for individuals experiencing stress as a result of the COVID-19 outbreak, recommended/mandatory social distancing, and other related stressors (e.g., loss of income, shortages of daily essentials, etc.). The program consists of 8 skills aimed at increasing the daily experience of positive emotion to help individuals cope with whatever stress they might be experiencing. The skills are presented over the course of 5 weeks and after learning each skill by reading through content on our platform, there is the opportunity to practice the skill on the platform as well.

•At least 18 years of age

•Speaks and reads English

•Able to access the online platform through their phone, a public device (i.e., at the library) or at home

•Lives in US

Moskowitz, JudithMoskowitz, Judith
STU00212262
More Info

For more information on this study please contact us:

Summers, Amanda +1 312 503 5247
Copy
COVID-19 Convalescent Blood BioBank (SeroCore)
Individuals will have blood drawn on enrollment as well as 6, 12 and 24 months later.  Blood will be used for genetic testing to identify factors associated with disease severity and immunologic responses.  Blood will be used to interrogate imm…
Individuals will have blood drawn on enrollment as well as 6, 12 and 24 months later.  Blood will be used for genetic testing to identify factors associated with disease severity and immunologic responses.  Blood will be used to interrogate immunologic responses over time.  Blood will be shared with other investigators to validate serologic testing assays and to facilitate vaccine development.  
Individuals who have recovered from COVID-19 are eligible for enrollment.  Patients will need to be confirmed to have had COVID-19 either through PCR testing or a positive antibody test prior to enrollment.  
Ison, Michael GIson, Michael G
  • Map it 676 N. Saint Clair St. Suite 940
    Chicago, IL
STU00212371
More Info

For more information on this study please contact us:

Goudy, Leah +1 312 694 0242
Copy
NU COVID-19 INT20L02 - International registry on thoracic cancer patients with COVID 19 - TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)
An early report of COVID-19 cases indicated that cancer patients had an increased risk of developing severe COVID-19-related symptoms compared to …
An early report of COVID-19 cases indicated that cancer patients had an increased risk of developing severe COVID-19-related symptoms compared to COVID-19 patients without cancer. The purpose of this registry is to collect clinical information like symptoms, treatments, and outcomes of thoracic cancer patients (NSCLC, SCLS, MPM, and TETs) with COVID-19 to help develop risk assessment strategies and treatment recommendations for thoracic cancer patients.

Participants 18 years or older who have a type of thoracic cancer; (Non-Small Cell Lung Carcinoma [NSCLC], Small CellLung Carcinoma [SCLC], Malignant Pleural Mesothelioma [MPM], or thymicepithelial tumor [TET]) and have also been diagnosed with COVID-19

Patel, Jyoti D DPatel, Jyoti D D
  • Map it 201 E. Huron St.
    Chicago, IL
STU00212311
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU COVID-19 MSK20H04: Examining COVID19 Course and Outcomes in Patients Previously Diagnosed with Chronic Lymphocytic Leukemia (CLL)
This multicenter, retrospective cohort study will include patientstreated at national and international medical centers. Patients will be included if they have a prior …
This multicenter, retrospective cohort study will include patientstreated at national and international medical centers. Patients will be included if they have a prior diagnosis of CLL, havebeen diagnosed with COVID19, and received care at a participating medicalcenter.

Primary Aim:

To determine the 28-daymortality rate from the time of COVID 19 diagnosis for CLL patients infectedwith SARS-CoV2 at MSKCC and other institutions.

Secondary Aims:

To describe baseline characteristics, prior and current CLL directed therapies, COVID19 clinical course and outcomes for CLL patients infected with SARS-CoV2.

To examine relationships between CLL directed therapy and COVID19 disease course and outcomes.

To examine current practices regarding management of CLL directed therapy in CLL patients infected with SARS-CoV2.

Chronic lymphocytic leukemia (CLL) patients diagnosed with COVID19.
Ma, ShuoMa, Shuo
  • Map it 251 E. Huron St.
    Chicago, IL
STU00212455
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Wearable sensor to monitor and track COVID-19-like signs and symptoms to develop better care strategies for COVID-19 pandemic
Specific Aims:1. Develop a wearable sensor package to gather data on COVID-19-like signs andsymptoms such as elevated body temperature, respiratory parameters, heart rate ,cou…
Specific Aims:1. Develop a wearable sensor package to gather data on COVID-19-like signs andsymptoms such as elevated body temperature, respiratory parameters, heart rate ,coughand gait.2. Create algorithms to monitor and track changes to COVID19-like signs and symptomsfor developing a better care and isolation strategies for COVID-19 pandemic

Ages between 18-95 years old

Currently experiencing any COVID-like signs and symptoms such as fever, cough,shortness of breath, trouble breathing, persistent pain or pressure in the chest, confusionor inability to arouse, bluish lips or face
Jayaraman, ArunJayaraman, Arun
  • Map it 201 E. Huron St.
    Chicago, IL
STU00212522
More Info

For more information on this study please contact us:

McGee, Lori Lyn Lyn 312 238 2091
Copy
Screening for Coronavirus Antibodies in Neighborhoods (SCAN)
Inthe SCAN study, we are measuring how many people in the Chicagoland area haveantibodies to SARS-CoV-2 (the virus that causes COVID-19), how widespread theinfection has been in Chicago, and whether some neighborhoods had moreinfection than…
Inthe SCAN study, we are measuring how many people in the Chicagoland area haveantibodies to SARS-CoV-2 (the virus that causes COVID-19), how widespread theinfection has been in Chicago, and whether some neighborhoods had moreinfection than others. By taking part, you will help us find out how many peoplein specific areas have been exposed to SARS-CoV-2, and if these antibodiesprotect people against re-infection.

Adults age 18 years and older living in the Chicagoland area or Illinois.

McDade, ThomasMcDade, Thomas
STU00212472
More Info

For more information on this study please contact us:

Saber, Rana +1 312 503 5430
Copy
Effects of the COVID-19 Pandemic on Sexual and/or Gender Minority (SGM) Individuals and People with HIV (PWH)

Let’s find out the pandemic’s impact on the LGBTQ+ community and those living with HIV - by taking this national survey from home! The goal is to understand how COVID-19 and the U.S. r…

Let’s find out the pandemic’s impact on the LGBTQ+ community and those living with HIV - by taking this national survey from home! The goal is to understand how COVID-19 and the U.S. response impacts your community in order to help build better health care, policy, and support systems. - by taking this national survey from home!

The goal is to understand how COVID-

19 and the U.S. response impacts your community in order to help build better health

care, policy, and support systems.

We are looking for people who are LGBTQ+ and/or people who are HIV-positive to be in this study. You must be 18 years of age or older and a current resident of the United States to participate.
Phillips ii, GregoryPhillips ii, Gregory
  • Map it 633 N. St. Clair St.
    Chicago , IL
  • Map it 680 N. Lake Shore Drive Suite 1410
    Chicago, IL
STU00212293
More Info

For more information on this study please contact us:

Felt, Dylan 312 503 3799
Copy
ACTIV-2/A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)

ACTIV-2/A5401 is a master protocol to evaluate the safety and efficacy ofinvestigational agents for the treatment of symptomatic non-hospitalized adultswith COVID-19.

This study is being done to…

ACTIV-2/A5401 is a master protocol to evaluate the safety and efficacy ofinvestigational agents for the treatment of symptomatic non-hospitalized adultswith COVID-19.

This study is being done to rapidly and efficiently evaluate multiple potentialtherapeutics for COVID-19 in an outpatient setting.

Duration of study: 28 days of intensive follow-up, followedby limited follow-up through 24 weeks.

  • Ambulatory (non-hospitalized) adult (18 years or older)
  • Active COVID-19 infection within 7 days prior to Entry
  • At least one typical COVID-19 symptom for within 10 days prior to Entry, plus one the following symptoms present within 48 hours of entry:

–Fever or feeling feverish, cough, shortness of breath atrest or with activity, sore throat, body or muscle pain, fatigue, headache,chills

Taiwo, Babafemi OTaiwo, Babafemi O
  • Map it 201 E. Huron St.
    Chicago, IL
NCT04518410 STU00213144
More Info
COVID

For more information on this study please contact us:

Berzins, Baiba Ingrida +1 312 695 5012
Copy
COVID Prevention Trials Registry
Afteryou provide consent, you will be asked to complete a survey to collect some informationabout your health and risk of exposure to COVID. The study team may contact you to assess yourpotential eligibility for COVID prevention trials when they open. You may open th…
Afteryou provide consent, you will be asked to complete a survey to collect some informationabout your health and risk of exposure to COVID. The study team may contact you to assess yourpotential eligibility for COVID prevention trials when they open. You may open the consent and registry survey in your web browser by clickingthe link below: COVID PreventionTrials Registry Consent . If thelink above does not work, try copying the link below into your web browser: https://is.gd/NUVaccineStudy
The NorthwesternCOVID Prevention Trials Registry is open to all adults who are interested inbeing contacted about upcoming COVID vaccine and other prevention studies.

TheCOVID vaccine trials will enrollpersonswhoareatrisk of infection and COVID-19 disease. This· · · - - - Racial/ethnic groups such as African Americans, Latinx, and NativeAmericanpopulations.

Krueger, KarenKrueger, Karen
STU00213110
More Info
COVID

For more information on this study please contact us:

Berzins, Baiba Ingrida +1 312 695 5012
Copy
COVID-19 TestUS an initiative of RADx AcceleRATeD study (Rapid Assessment of Technology for SARS-CoV-2 Detection)

We are studying the accuracy and usability of NEW point-of-care COVID-19 diagnostic tests compared to standard laboratory testing. You will be asked to come to our clinic for ONE visi…

We are studying the accuracy and usability of NEW point-of-care COVID-19 diagnostic tests compared to standard laboratory testing. You will be asked to come to our clinic for ONE visit to collect nasal swabs (less than one inch into each nostril) for new and standard tests. You will also complete surveys through a web browser, App on mobile device, or telephone interview with research staff. These surveys take approximately 30 minutes and they collect information on prior COVID-19 testing, COVID-19 exposures, demographics, and brief medical history.

Adults and children (over 10 years of age) with or without symptoms who are interested in getting tested for COVID-19 and willing to complete on-line or verbal surveys.

Murphy, Robert LeoMurphy, Robert Leo
  • Map it Arkes Pavilion, 676 N. Saint Clair St. Suite 940
    Chicago, IL
STU00213330
More Info

For more information on this study please contact us:

Murphy, Robert Leo +1 312 503 8379
Copy
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

The AZD1222 COVID-19VACCINE Study is researching an investigational vaccin…

The AZD1222 COVID-19VACCINE Study is researching an investigational vaccine for the prevention of COVID-19, the disease caused by the new coronavirus (SARS-CoV-2). The studywill see how safe the investigational vaccine is and how well it works.

Participants will berandomly assigned (by chance) to receive 2 injections of either theinvestigational vaccine or placebo.

If you take part, you willbe in the study for approximately 2 years and will require up to 10 visits toour study center. Additional visits may be required if you develop symptoms ofCOVID-19 during the study. Your health will be monitored carefully by a team ofdoctors and nurses throughout the study. The study injections, healthassessments, and medical tests related to the study will be provided at no costto you.

You may be able to take part in the AZD1222 COVID-19 VACCINE Study if you:

- Are 18 years of age or older

- Are in good or stable health (you may have an underlying medical condition and still take part, if your disease is stable)

- Have an increased risk of getting COVID-19

- Do not have a previously confirmed diagnosis of COVID-19

Taiwo, Babafemi OTaiwo, Babafemi O
  • Map it 676 N. Saint Clair St. Suite 940
    Chicago, IL
STU00213385
More Info
COVID Vaccine

For more information on this study please contact us:

Berzins, Baiba Ingrida +1 312 695 5012
Copy
Back to top